The Prognostic Relevance of Fascin Expression in Human Gastric Carcinoma

Hashimoto, Yuichi; Shimada, Yutaka; Kawamura, Junichiro; Yamasaki, Seiji; Imamura, Masayuki

doi:10.1159/000081327

Cited by 149 publications

(157 citation statements)

References 48 publications

Supporting

Mentioning

141

Contrasting

Order By: Relevance

“…Fascin immunoreactivity was not associated with the tumour proliferation fraction as assessed by the Ki-67-labelling index, at variance with previous studies of lung and stomach cancers and also of colonic cell cultures (Jawhari et al, 2003;Pelosi et al, 2003b;Hashimoto et al, 2004). In a recent work on CRC, similar to the current one, comparing fascin expression with Ki-67 immunostaining, a lack of direct association between the two markers was noted, indicating that the fascin upregulation do not correlate positively with cell proliferation (Hashimoto et al, 2006).…”

Section: >100contrasting

confidence: 66%

“…The main results are that fascin is upregulated in most colonic carcinomas, correlating with a higher tumour grade, right tumour location and tumour stage, and that fascin immunoreactivity is an independent predictor of reduced OS and DFS in patients with advanced tumour stage. A growing body of literature reports that fascin is expressed in many types of transformed epithelial cell lines and in several solid neoplasms (Grothey et al, 2000;Hu et al, 2000;Goncharuk et al, 2002;Jawhari et al, 2003;Pelosi et al, 2003a, b;Hashimoto et al, 2004Hashimoto et al, , 2005aHashimoto et al, , 2006Tong et al, 2005;Xie et al, 2005;Yoder et al, 2005;Choi et al, 2006;Zhang et al, 2006) where it correlates with tumour stage (Hashimoto et al, 2004(Hashimoto et al, , 2005aYoder et al, 2005;Choi et al, 2006) and grade (Pelosi et al, 2003b;Hashimoto et al, 2004;Yoder et al, 2005), pT class (Hashimoto et al, 2004(Hashimoto et al, , 2005a, lymph node involvement (Hashimoto et al, 2004(Hashimoto et al, , 2005aChoi et al, 2006;Zhang et al, 2006), recurrence (Hashimoto et al, 2004), and both OS (Hashimoto et al, 2004(Hashimoto et al, , 2005a(Hashimoto et al, , 2006Yoder et al, 2005) and DFS (Pelosi et al, 2003b;Yoder et al, 2005). The close association we found between fascin immunoreactivity and tumour stage, tumour grade, the number and type of lymph node involvement, and distant metastasis indicates the major role of fascin in the progression of colonic adenocarcinoma.…”

Section: Discussionmentioning

confidence: 99%

“…Although the clinical implications of colorectal mucinous carcinoma are still controversial, a consensus conference on colorectal carcinomas stated that mucinous and signet ring carcinomas, when evaluated jointly, have a poorer prognosis than intestinal-type adenocarcinomas (Compton et al, 2000). Although the association of fascin expression with lymph node involvement has already been documented for other gastrointestinal cancers such as oesophageal and gastric carcinomas (Hashimoto et al, 2004(Hashimoto et al, , 2005a and also for pulmonary neoplasms (Pelosi et al, 2003a;Choi et al, 2006), we have shown that fascin immunoreactivity in colonic adenocarcinomas is also related to the patterns of lymph node involvement (intra-vs extra-lymph nodal colonisation). As fascin immunoreactivity is also associated with the number of metastatic lymph nodes and the occurrence of distant metastases, we hypothesise that this molecule is very likely involved in the metastatic process of colonic adenocarcinoma cells via its motility-inducing properties.…”

Section: >100mentioning

confidence: 99%

“…Moreover, the protein promotes cell locomotion (Yamashiro et al, 1998) and participates in the mechanical organisation of stress fibres (Adams, 1997). A definite overexpression of fascin has been reported in carcinomas of different organs, including oesophagus (Hashimoto et al, 2005a;Xie et al, 2005;Zhang et al, 2006), stomach (Hashimoto et al, 2004), colon (Jawhari et al, 2003;Hashimoto et al, 2006), pancreas (Maitra et al, 2002), breast (Grothey et al, 2000;Yoder et al, 2005), skin (Goncharuk et al, 2002), lung (Pelosi et al, 2003a, b;Choi et al, 2006), urinary bladder (Tong et al, 2005), and ovary (Hu et al, 2000) and the protein has been recently proposed as a novel biomarker for aggressive tumour behaviour (Hashimoto et al, 2005b(Hashimoto et al, , 2006Zhang et al, 2006). In colonic adenocarcinoma cell lines, fascin overexpression correlates with an increase in the formation of dynamic cell protrusions, proliferation, and invasiveness (Jawhari et al, 2003).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma

et al. 2007

View full text Add to dashboard Cite

Fascin, an actin-bundling protein involved in cell motility, has been shown to be upregulated in several types of carcinomas. In this study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up. Fascin expression was compared with several clinicopathologic parameters and survival. Overall, fascin immunoreactivity was detected in 162 (71%) tumours with a prevalence for right-sided tumours (Po0.001). Fascin correlated significantly with sex, tumour grade and stage, mucinous differentiation, number of metastatic lymph nodes, extranodal tumour extension, and the occurrence of distant metastases. Patients with fascin-expressing tumours experienced a shorter disease-free and overall survival in comparison with those with negative tumours, and fascin immunoreactivity emerged as an independent prognostic factor in the multivariate analysis. Moreover, patients with the same tumour stages could be stratified in different risk categories for relapse and progression according to fascin expression. Our findings suggest that fascin is a useful prognostic marker for colonic adenocarcinomas.

show abstract

Section: >100contrasting

confidence: 66%

Section: Discussionmentioning

confidence: 99%

Section: >100mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Overexpression of fascin‐1 has been reported in several types of carcinoma, including that of the lung 8, colon 9, stomach 10, ovary 11, and breast 12. In a previous study of breast cancer, fascin‐1 expression was associated with TNBC in African American women.…”

Section: Introductionmentioning

confidence: 99%

Fascin‐1 as a novel diagnostic marker of triple‐negative breast cancer

et al. 2016

View full text Add to dashboard Cite

In some cases of breast cancer, diagnosis of triple‐negative breast cancer (TNBC) requires further fluorescence in situ hybridization (FISH) for determining human epidermal growth factor receptor 2 (HER2) status. However, few cases undergo FISH in China, leading to difficulty regarding subsequent treatment decisions. Here, we used immunohistochemical analysis to explore expression of fascin‐1, an actin‐bundling protein, as a diagnostic marker of TNBC. A total of 457 cases of breast cancer were divided into four molecular subtypes, including 82 cases (17.9%) of TNBC, 81 (17.7%) of HER2‐enriched, 185 (40.5%) of luminal A, and 109 (23.9%) of luminal B. Positive fascin‐1 expression was seen in 144 cases (31.5%), including 77 (16.8%) strong positive cases. Rates of positive and strong positive expression of fascin‐1 were significantly higher in cases of TNBC than in the other molecular subtypes. In all cases of breast cancer, the sensitivities and specificities of positive and strong positive fascin‐1 expression for predicting TNBC were 87.8% and 80.8%, and 78.0% and 96.5%, respectively. In cases of hormone receptor–negative breast cancer, the sensitivities and specificities of positive and strong positive fascin‐1 expression for predicting TNBC were 87.8% and 61.7%, and 78.0% and 92.6%, respectively. In 24 cases with estrogen receptor (ER)‐, PR‐, and HER2 2 + equivocal status who underwent FISH, the sensitivity and specificity of strong positive fascin‐1 expression for predicting TNBC were 71.4% and 90.0%. These results suggest that strong positive fascin‐1 expression can be used as a diagnostic marker of TNBC.

show abstract

Multiple Pools of Nuclear Actin

Wineland

Kelpsch

Tootle

2018

The Anatomical Record

View full text Add to dashboard Cite

While nuclear actin was reported ~50 years ago, it’s in vivo prevalence and structure remain largely unknown. Here we use Drosophila oogenesis, i.e. follicle development, to characterize nuclear actin. We find that three different reagents – DNase I, anti-actin C4, and anti-actin AC15 – recognize distinct pools of nuclear actin. DNase I labels monomeric or G-actin, and, during follicle development, G-actin is present in the nucleus of every cell. Some G-actin is recognized by the C4 antibody. In particular, C4 nuclear actin colocalizes with DNase I to the nucleolus in anterior escort cells, follicle stem cells, some mitotic follicle cells, and a subset of nurse cells during early oogenesis. C4 also labels polymeric nuclear actin in the nucleoplasm of the germline stem cells, early cystoblasts, and oocytes. The AC15 antibody labels a completely distinct pool of nuclear actin from that of DNase I and C4. Specifically, AC15 nuclear actin localizes to the chromatin in the nurse and follicle cells during mid-to-late oogenesis. Within the oocyte, AC15 nuclear actin progresses from localizing to puncta surrounding the DNA, to forming a filamentous cage around the chromosomes. Together these findings reveal that nuclear actin is highly prevalent in vivo, and multiple pools of nuclear actin exist and can be recognized using different reagents. Additionally, our localization studies suggest that nuclear actin may regulate stemness, nucleolar structure and function, transcription, and nuclear structure. Such findings call for further studies to explore the prevalence, diversity, and functions of nuclear actin across tissues and organisms.

show abstract

The Prognostic Relevance of Fascin Expression in Human Gastric Carcinoma

Cited by 149 publications

References 48 publications

Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma

Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma

Fascin‐1 as a novel diagnostic marker of triple‐negative breast cancer

Multiple Pools of Nuclear Actin

Contact Info

Product

Resources

About